Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety and tolerability of combination therapy of
SGN-40 with gemcitabine and rituximab for the treatment of lymphoma. This study is also
intended to estimate how well your disease responds to this treatment.